Comorbidities and their impact on chronic obstructive pulmonary disease

DURSUNOĞLU N., KÖKTÜRK N., Baha A., Bilge A. K., Borekci S., ÇİFTCİ F., ...Daha Fazla

TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, cilt.64, sa.4, ss.289-298, 2016 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 64 Sayı: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5578/tt.2245
  • Dergi Adı: TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.289-298
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Chronic obstructive pulmonary disease (COPD) is a complex disease that is associated with devastating outcomes resulting from lung involvement and several comorbidities. Comorbidities could impact on symptomology, quality of life, the complications, the management, economic burden and the mortality of the disease. The importance of comorbidities originates from their impact on the outcome of COPD. The most frequent comorbidities in COPD are cardiovascular, endocrinological, musculoskeletal, phycological disorders and lung cancer. Almost 50% of the COPD patients have 3 or more comorbidities. The recent Global Initiative of Obstructive Lung Disease (GOLD) Guideline suggested proactive search and the treatment of the comorbidities. However, there is no certain evidence demonstrating that active treatment of comorbidities improve the outcomes of COPD. However, it is well known that several comorbidities such as cardiovascular disease and lung cancer have greater impact on mortality caused by COPD. Several studies have shown that Charlson Comorbidity index or more recenty COPD Specific Comorbidity Index (COTE) has been found to be related with mortality of COPD. This concise review intended to summarize the most frequent comorbidities in association with their impact on COPD.